Logo image of OKUR

ONKURE THERAPEUTICS INC-A (OKUR) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:OKUR - US68277Q1058 - Common Stock

2.9 USD
+0.05 (+1.75%)
Last: 12/31/2025, 8:22:15 PM
Fundamental Rating

2

Taking everything into account, OKUR scores 2 out of 10 in our fundamental rating. OKUR was compared to 530 industry peers in the Biotechnology industry. OKUR has a great financial health rating, but its profitability evaluates not so good. OKUR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year OKUR has reported negative net income.
OKUR had a negative operating cash flow in the past year.
In the past 5 years OKUR always reported negative net income.
In the past 5 years OKUR always reported negative operating cash flow.
OKUR Yearly Net Income VS EBIT VS OCF VS FCFOKUR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

OKUR's Return On Assets of -111.50% is on the low side compared to the rest of the industry. OKUR is outperformed by 77.55% of its industry peers.
OKUR has a Return On Equity (-122.25%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -111.5%
ROE -122.25%
ROIC N/A
ROA(3y)-55.3%
ROA(5y)-45.4%
ROE(3y)-63.34%
ROE(5y)-51.1%
ROIC(3y)N/A
ROIC(5y)N/A
OKUR Yearly ROA, ROE, ROICOKUR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OKUR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OKUR Yearly Profit, Operating, Gross MarginsOKUR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

OKUR has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, OKUR has less shares outstanding
OKUR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
OKUR Yearly Shares OutstandingOKUR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
OKUR Yearly Total Debt VS Total AssetsOKUR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

OKUR has an Altman-Z score of -2.85. This is a bad value and indicates that OKUR is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of OKUR (-2.85) is comparable to the rest of the industry.
There is no outstanding debt for OKUR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.85
ROIC/WACCN/A
WACCN/A
OKUR Yearly LT Debt VS Equity VS FCFOKUR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 11.45 indicates that OKUR has no problem at all paying its short term obligations.
OKUR has a Current ratio of 11.45. This is amongst the best in the industry. OKUR outperforms 86.04% of its industry peers.
A Quick Ratio of 11.45 indicates that OKUR has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 11.45, OKUR belongs to the best of the industry, outperforming 86.04% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.45
Quick Ratio 11.45
OKUR Yearly Current Assets VS Current LiabilitesOKUR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

OKUR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 61.06%, which is quite impressive.
EPS 1Y (TTM)61.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, OKUR will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.26% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y29.21%
EPS Next 2Y19.23%
EPS Next 3Y14.82%
EPS Next 5Y13.26%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OKUR Yearly Revenue VS EstimatesOKUR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 200K 400K 600K 800K 1M
OKUR Yearly EPS VS EstimatesOKUR Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OKUR. In the last year negative earnings were reported.
Also next year OKUR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OKUR Price Earnings VS Forward Price EarningsOKUR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OKUR Per share dataOKUR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

OKUR's earnings are expected to grow with 14.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.23%
EPS Next 3Y14.82%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OKUR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ONKURE THERAPEUTICS INC-A

NASDAQ:OKUR (12/31/2025, 8:22:15 PM)

2.9

+0.05 (+1.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)03-09 2026-03-09/amc
Inst Owners82.56%
Inst Owner Change0.7%
Ins Owners1.63%
Ins Owner Change0.67%
Market Cap39.30M
Revenue(TTM)N/A
Net Income(TTM)-81.21M
Analysts85
Price Target26.01 (796.9%)
Short Float %0.43%
Short Ratio0.36
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.62%
Min EPS beat(2)10.44%
Max EPS beat(2)10.8%
EPS beat(4)3
Avg EPS beat(4)-10.04%
Min EPS beat(4)-81.5%
Max EPS beat(4)20.09%
EPS beat(8)4
Avg EPS beat(8)-9.79%
EPS beat(12)7
Avg EPS beat(12)-7.35%
EPS beat(16)11
Avg EPS beat(16)-2.06%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.56%
PT rev (3m)-15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.49%
EPS NY rev (1m)0.26%
EPS NY rev (3m)0.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.59
P/tB 0.59
EV/EBITDA N/A
EPS(TTM)-4.79
EYN/A
EPS(NY)-3.8
Fwd EYN/A
FCF(TTM)-4.53
FCFYN/A
OCF(TTM)-4.53
OCFYN/A
SpS0
BVpS4.9
TBVpS4.9
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -111.5%
ROE -122.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.3%
ROA(5y)-45.4%
ROE(3y)-63.34%
ROE(5y)-51.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.42%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.45
Quick Ratio 11.45
Altman-Z -2.85
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)176.74%
Cap/Depr(5y)196.04%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0.91%
EPS Next Y29.21%
EPS Next 2Y19.23%
EPS Next 3Y14.82%
EPS Next 5Y13.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-81.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.4%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-2.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.01%
OCF growth 3YN/A
OCF growth 5YN/A

ONKURE THERAPEUTICS INC-A / OKUR FAQ

Can you provide the ChartMill fundamental rating for ONKURE THERAPEUTICS INC-A?

ChartMill assigns a fundamental rating of 2 / 10 to OKUR.


What is the valuation status for OKUR stock?

ChartMill assigns a valuation rating of 0 / 10 to ONKURE THERAPEUTICS INC-A (OKUR). This can be considered as Overvalued.


Can you provide the profitability details for ONKURE THERAPEUTICS INC-A?

ONKURE THERAPEUTICS INC-A (OKUR) has a profitability rating of 0 / 10.


What is the financial health of ONKURE THERAPEUTICS INC-A (OKUR) stock?

The financial health rating of ONKURE THERAPEUTICS INC-A (OKUR) is 7 / 10.